ethyl (1,3-dioxobenzo[c]azolidin-2-yloxy)formate | 99972-91-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: ethyl (1,3-dioxobenzo[c]azolidin-2-yloxy)formate
• 英文别名: O-carbethoxy-N-hydroxyphthalimide；N-(Ethoxycarbonyloxy)phthalimide；(1,3-dioxoisoindol-2-yl) ethyl carbonate
• CAS: 99972-91-5
• 化学式: C₁₁H₉NO₅
• 分子量: 235.196
• InChiKey: VXEAWVMTERBHFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-N-(thiophen-2-ylmethyl)benzene-1,2,4-triamine 、 ethyl (1,3-dioxobenzo[c]azolidin-2-yloxy)formate 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以0.037 g的产率得到N-{2-amino-4-[(2-thienylmethyl)amino]phenyl}ethoxycarboxamide
  参考文献：
  名称：

  高效KCNQ2 / 3-特定通道激活剂的合成和评估。

  摘要：

  KQT样亚家族（KCNQ）通道是电压门控的非灭活钾离子通道，其下调与多种与过度兴奋性相关的疾病有关，包括癫痫，神经性疼痛和耳鸣。这些通道的激活剂降低了中枢和周围神经元的兴奋性，因此具有治疗作用。在这里，我们合成了KCNQ2-5通道激活剂瑞替加滨的几个部分，这是美国食品和药物管理局批准的抗惊厥药。通过在苄胺部分的4位上引入CF3-基团并在苯胺环的3位上引入氟原子，我们生成了乙基（2-氨基-3-氟-4-（（4-（三氟甲基）苄基）氨基）苯基）氨基甲酸酯（RL648_81），一种新的KCNQ2 / 3特异性活化剂，其> 比瑞替加滨强15倍，而且选择性更高。我们建议RL648_81是用于治疗或预防与神经元过度兴奋有关的神经系统疾病的有前途的临床候选药物。

  DOI：

  10.1124/mol.115.103200
• 作为产物：
  描述：

  N-羟基邻苯二甲酰亚胺 在 萘 、 lithium 作用下， 以 四氢呋喃 为溶剂， 反应 28.0h， 生成 ethyl (1,3-dioxobenzo[c]azolidin-2-yloxy)formate
  参考文献：
  名称：

  高活性锰与CO交叉偶联反应合成N-羟基邻苯二甲酰亚胺酯

  摘要：

  DOI：

  10.1002/bkcs.11461

文献信息

• [EN] (2-AMINO-4(ARYLAMINO)PHENYL) CARBAMATES<br/>[FR] CARBAMATES (2-AMINO-4(ARYLAMINO)PHÉNYL)
  申请人：UNIV PITTSBURGH

  公开号：WO2016077724A1

  公开（公告）日：2016-05-19

  A compound, or pharmaceutically acceptable salt thereof, having a formula (I) wherein R1 is H or optionally-substituted alkyl; R2 is optionally-substituted alkyl; R3 and R4 are each independently H or optionally-substituted alkyl; R5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R6 and R7 are each independently H, deuterium, optionally- substituted alkyl, or R6 and R7 together form a carbocyclic; R8 is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R8 is 4-halophenyl, then R2 is substituted alkyl or branched alkyl or at least one of R6 or R7 is not H; and R30, R31 and R32 are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy.

  一种化合物，或其药学上可接受的盐，其具有以下式(I)：其中R1为H或可选择性取代的烷基；R2为可选择性取代的烷基；R3和R4各自独立地为H或可选择性取代的烷基；R5为H、可选择性取代的烷基、酰基或烷氧羰基；R6和R7各自独立地为H、氘、可选择性取代的烷基，或R6和R7一起形成一个环烷基；R8为可选择性取代的噻唑基、可选择性取代的噻吩基，或取代的苯基，但如果R8为4-卤苯基，则R2为取代的烷基或支链烷基，或者R6或R7中至少一个不是H；而R30、R31和R32各自独立地为H、氘、卤素、取代的烷硫基，或可选择性取代的烷氧基。
• Synthesis and anticonvulsant activity of imidooxy derivatives
  作者：Ivan O. Edafiogho、K. R. Scott、Jacqueline A. Moore、Vida A. Farrar、Jesse M. Nicholson

  DOI：10.1021/jm00105a059

  日期：1991.1

  Previous results of anticonvulsant activity in several imidooxy carboxylates related to (aminooxy)acetic acid in young chicks, prompted an in-depth reinvestigation of these analogues in mice. A series of 22 succinimidooxy, phthalimidooxy, and naphthalimidooxy carboxylates were synthesized and evaluated for anticonvulsant activity by the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS). Methyl (succinimidooxy)acetate (2d), ethyl (succinimidooxy)acetate (2e), methyl (phthalimidooxy)acetate (3d), ethyl (phthalimidooxy)acetate (3e), and ethyl 2-(phthalimidooxy)propionate (3g), which were initially found to be active as anticonvulsants in young chicks were uniformly inactive in the Phase I seizure tests involving maximal electroshock (MES), pentylenetetrazol (scMet), or neurologic toxicity toxicity (Tox). Several newer analogues, ethyl (succinimidooxy)formate (2c) and methyl 3-(phthalimidooxy)-2-methylacrylate (4h) were found to be active in the scMet (3a) or both (4h) evaluations. Most interesting was the anticonvulsant results of N-(benzyloxy)-2-azaspiro[4.4]nonane-1,3-dione (5b), which displayed anti-MES activity and a protective index (TD50/ED50) of > 4.5.
• Carbethoxylating Agents as Inhibitors of Aldehyde Dehydrogenase
  作者：Herbert T. Nagasawa、Eugene G. DeMaster、David J. W. Goon、Sagar P. Kawle、Frances N. Shirota

  DOI：10.1021/jm00011a006

  日期：1995.5

  N, O-Dicarbethoxy-4-chlorobenzenesulfohydroxamate (1c) and O-carbethoxy-N-hydroxysaccharin (6), both potential carbethoxylating agents, inhibited yeast aldehyde dehydrogenase (AlDH) with IC50)s Of 24 and 56 mu M, respectively. The esterase activity of the enzyme was commensurably inhibited. AlDH activity was only partially restored on incubation with mercaptoethanol (20 mM) for 1 h. On incubation with rat plasma, 1c liberated nitroxyl, a potent inhibitor of AlDH. Under the same conditions, nitroxyl generation from 6 was minimal, a result compatible with a previous observation that nitroxyl generation from N-hydrxxysaccharin (7), the product of the hydrolysis of the carbethoxy group of 6, was minimal at physiological pH. Since chemical carbethoxylating agents represented by the O-carbethoxylated N-hydroxyphthalimide, 1-hydroxybenzotriazole, and N-hydroxysuccinimide (8, 9, and 10, respectively) likewise inhibited yeast AlDH, albeit with IC50's 1 Order of magnitude higher, we postulate that 1c and 6 act as irreversible inhibitors of AlDH by carbethoxylating the active site of the enzyme.
• EDAFIOGHO, IVAN O.;SCOTT, K. R.;MOORE, JACQUELINE A.;FARRAR, VIDA A.;NICH+, J. MED. CHEM., 34,(1991) N, C. 387-392
  作者：EDAFIOGHO, IVAN O.、SCOTT, K. R.、MOORE, JACQUELINE A.、FARRAR, VIDA A.、NICH+

  DOI：——

  日期：——
• (2-AMINO-4-(ARYLAMINO)PHENYL) CARBAMATES
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20180127357A1

  公开（公告）日：2018-05-10

  A compound, or pharmaceutically acceptable salt thereof, having a formula I of: wherein R 1 is H or optionally-substituted alkyl; R 2 is optionally-substituted alkyl; R 3 and R 4 are each independently H or optionally-substituted alkyl; R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocyclic; R 8 is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R 8 is 4-halophenyl, then R 2 is substituted alkyl or branched alkyl or at least one of R 6 or R 7 is not H; and R 30 , R 31 and R 32 are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy.